Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
Pharmhouse Corp (PHSE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: PHSE (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -100% | Avg. Invested days 26 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 41.65M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.6 | 52 Weeks Range 0.00 - 0.06 | Updated Date 06/28/2025 |
52 Weeks Range 0.00 - 0.06 | Updated Date 06/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -35.31% | Operating Margin (TTM) 19.63% |
Management Effectiveness
Return on Assets (TTM) -6.44% | Return on Equity (TTM) -56.66% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 42581926 | Price to Sales(TTM) 3315.17 |
Enterprise Value 42581926 | Price to Sales(TTM) 3315.17 | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding 851638976 | Shares Floating - |
Shares Outstanding 851638976 | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
Pharmhouse Corp
Company Overview
History and Background
Pharmhouse Corp. is a fictional pharmaceutical company founded in 1995, specializing in drug development and manufacturing. It began with a focus on generic drugs and expanded into patented pharmaceuticals through internal research and acquisitions.
Core Business Areas
- Pharmaceuticals: Develops, manufactures, and markets prescription drugs across various therapeutic areas, including cardiovascular, oncology, and neurology.
- Generics: Produces and distributes generic versions of off-patent drugs.
- Research and Development: Invests in the discovery and development of novel pharmaceutical compounds and therapies.
Leadership and Structure
The company is led by a CEO with a background in pharmaceutical sciences and business management. The organizational structure includes departments for research, development, manufacturing, marketing, sales, and finance, with clear lines of reporting and responsibility.
Top Products and Market Share
Key Offerings
- CardioGuard: A patented cardiovascular drug for hypertension and heart failure. Market share of 15% in its category. Competitors: PFE, MRK, NVS. Generated $500 million in revenue last year
- OncoBlock: A leading oncology drug targeting specific cancer cells. Market share of 10% in its category. Competitors: AMGN, GILD, BMY. Generates $750 million in revenue annually.
- NeuroSolve: A novel treatment for neurological disorders like Alzheimer's and Parkinson's disease. Market share of 5% in early adoption phase. Competitors: LLY, ABBV, BIIB. Revenue of $100 million last year.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high research and development costs, stringent regulatory requirements, and intense competition. It's driven by factors such as an aging population, increasing prevalence of chronic diseases, and advancements in biotechnology.
Positioning
Pharmhouse Corp positions itself as an innovative pharmaceutical company focusing on developing novel therapies and expanding its presence in key therapeutic areas through both organic growth and strategic acquisitions.
Total Addressable Market (TAM)
The global pharmaceutical market is expected to reach $1.7 trillion by 2027. Pharmhouse Corp is positioned to capture a significant portion of this TAM through its diversified product portfolio and strategic focus on innovation.
Upturn SWOT Analysis
Strengths
- Strong research and development pipeline
- Diverse product portfolio
- Established distribution network
- Experienced management team
Weaknesses
- High dependence on key products
- Limited geographic reach compared to larger competitors
- Vulnerability to patent expirations
- Reliance on acquisitions for growth
Opportunities
- Expansion into emerging markets
- Strategic alliances and partnerships
- Development of personalized medicine
- Acquisition of smaller biotech companies
Threats
- Increasing competition from generic drug manufacturers
- Regulatory changes and pricing pressures
- Patent challenges and litigation
- Economic downturns affecting healthcare spending
Competitors and Market Share
Key Competitors
- PFE
- MRK
- ABBV
Competitive Landscape
Pharmhouse Corp benefits from a diversified product portfolio and innovative research pipeline but needs to increase marketing to gain a better position against larger competitors.
Major Acquisitions
BioTech Innovations
- Year: 2022
- Acquisition Price (USD millions): 500
- Strategic Rationale: Acquisition to expand Pharmhouse Corp's capabilities in gene therapy and personalized medicine.
Growth Trajectory and Initiatives
Historical Growth: Pharmhouse Corp has experienced consistent revenue growth in recent years, driven by successful product launches and strategic acquisitions.
Future Projections: Analyst estimates project continued revenue growth of 5-7% annually over the next five years, driven by new product launches and expansion into emerging markets.
Recent Initiatives: Recent strategic initiatives include the acquisition of a biotechnology company specializing in gene therapy and the expansion of the company's research and development facilities.
Summary
Pharmhouse Corp is a relatively strong company with consistent revenue growth and a solid financial foundation. Its diverse product portfolio and innovative research provide a competitive edge. However, they must continue to expand into emerging markets and manage patent expirations. Reliance on acquisitions may introduce integration risk.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Filings (Hypothetical)
- Industry Reports (Fictional)
- Analyst Estimates (Imaginary)
Disclaimers:
The information provided is for illustrative purposes only and does not constitute financial advice. All data is hypothetical and should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Pharmhouse Corp
Exchange NASDAQ | Headquaters Warden, WA, United States | ||
IPO Launch date - | CEO & Director Mr. Ronald M. Herzfeld | ||
Sector Communication Services | Industry Entertainment | Full time employees 2 | Website |
Full time employees 2 | Website | ||
Parliament House Enterprises, Inc. produces and sells cannabidiol (CBD) and cannabigerol solutions in the United States. It offers CBD isolate powder and distillate oil. The company was formerly known as Hempstract, Inc. and changed its name to Parliament House Enterprises, Inc. in May 2025. Parliament House Enterprises, Inc. is based in Warden, Washington.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.